To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N
A phase 2 trial of Erlotinib in non-small-cell lung cancer and small-cell lung cancer, run by OBI Pharma, Inc, now recruiting.
Overview
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05442060 by OBI Pharma, Inc, with 60 participants planned, started 2022-07-27 and due to reach its primary completion in 2025-12-31. Interventions recorded: 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily). Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Shares Erlotinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE
Shares Erlotinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TermEGFR exon 19 deletion & L858R
Shares Erlotinib, Non-small-cell lung cancer.
- Treatmentcobas EGFR Mutation Test v2
Shares Erlotinib, Non-small-cell lung cancer.
- TermEGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)
Shares Erlotinib, Non-small-cell lung cancer.
- InstitutionGuangdong Provincial People's Hospital
Shares Erlotinib, Non-small-cell lung cancer.
- TermHistology
Shares Erlotinib, Non-small-cell lung cancer.